Catch Up on the Latest
Think about the last time you saw real-world data reshape your treatment approach—what if you discovered that one of our most trusted biologics behaves differently in deeper skin tones? In “The Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients With Atopic Dermatitis,” we peek behind the curtain at a patient group too often sidelined in clinical trials. Spoiler alert: preliminary findings hint that Black and African American adults on dupilumab for atopic dermatitis might actually experience fewer side effects than Caucasian patients.
Why should this matter to you? As dermatologists, we know that a treatment’s safety profile can make or break adherence. Yet so many of our pivotal studies under-represent deeper skin tones, leaving us to extrapolate—and sometimes over-or under-estimate risks. This retrospective chart review offers a welcome reality check on how dupilumab performs in day-to-day practice for patients with deeper skin tones. While the numbers aren’t big enough yet to draw definitive conclusions, they raise compelling questions about personalized care, risk counseling, and equitable trial design.
Ready to see the data and assess its impact on your practice? Dive into the full August JDD article to explore these trends, weigh their statistical heft, and consider how larger, multi-institutional efforts could confirm, or challenge, these early insights. It’s time to advocate for more inclusive research, fine-tune our patient conversations, and ensure that every patient receives the safest, most effective care possible.
Blog write-up assisted by AI
